FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
LOS ANGELES, July 17, 2017 -- Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Neurotrope, Inc. (“Neurotrope” or the “Company”) (Nasdaq:NTRP) for possible violations of federal securities laws from January 7, 2016 through April 28, 2017, inclusive (the “Class Period”). Investors who purchased or otherwise acquired Neurotrope shares during the Class Period should contact the firm by the July 17, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here.
You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or e-mail him at [email protected].
No class has been certified in the above action yet, and until a class is certified, you are not considered represented by an attorney. You may choose to do nothing and be an absent class member.
According to the Complaint, throughout the Class Period, Neurotrope issued materially false and misleading statements and/or failed to disclose material information, regarding the efficacy of its lead product candidate, Bryostatin-1. On May 1, 2017, Neurotrope issued a press release announcing “positive top-line results” of the pivotal Phase 2b trials of Bryostatin-1, noting “improvement in patients with moderate to severe Alzheimer’s disease.” The underlying trial data contradicted these representations, as the top-line data relating to the 20-microgram dose of Bryostatin-1 failed to produce results that were statistically significant. Also, Neurotrope failed to disclose statements regarding the efficacy of the 40-microgram dose with regard to its primary and secondary endpoints. Upon release of this news, the Company’s stock price dropped materially, which caused investors harm according to the Complaint.
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may constitute Attorney Advertising in certain jurisdictions under the applicable law and rules of ethics.
Contact: Lundin Law PC Brian Lundin, Esq. Telephone: 888-713-1033 Facsimile: 888-713-1125 [email protected] http://lundinlawpc.com/
